19/06/2006 - Pall’s pre-tax profits fell slightly in the first quarter of 2006 but its Biopharmaceuticals division has once again performed strongly, so speculation is rife as to whether it will escape an announced 10 per cent reduction of the filtration and separations giant’s global manufacturing workforce. The US company said its most pressing challenge is to reduce cost of sales and drive gross margin improvement across all businesses after its pre-tax profit dipped from $56.6m (€45m) in Q3 of 2005 to $54.3m in Q3 of 2006.
